Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis

Background: Glecaprevir/pibrentasvir (G/P; 300 mg/120 mg) is a new direct-acting antiviral (DAA) that exhibits anti-hepatitis C virus (HCV) pan-genotype (GT) activity for 8, 12, or 16 weeks. However, the U.S. Food and Drug Administration have received reports that using G/P causes moderate to severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Hsuan-Yu, Hung, Wei-Liang, Shih, Chia-Lung, Chen, Chung-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725884/
https://www.ncbi.nlm.nih.gov/pubmed/34969349
http://dx.doi.org/10.1080/07853890.2021.2012589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725884/
https://www.ncbi.nlm.nih.gov/pubmed/34969349
http://dx.doi.org/10.1080/07853890.2021.2012589

Ejemplares similares